Search Results

Your search for Neil Vasan, MD, PhD, and Maura N. Dickler, MD,Neil Vasan, MD, PhD, and Maura N. Dickler, MD matches 2 pages

Showing 1 - 2

By Caroline Helwick / October 10, 2017 / 2017 ESMO Congress

Abemaciclib Plus Endocrine Therapy Extends Progression-Free Survival in First-Line Therapy for Advanced Breast Cancer

THE VALUE OF cyclin-dependent kinase 4/6 (CDK4/6) inhibitors in advanced breast cancer became ever more certain with the announcement of interim data from MONARCH 3, which evaluated abemaciclib in combination with endocrine therapy as first-line therapy for hormone receptor–positive/HER2-negative...

breast cancer

By Neil Vasan, MD, PhD, and Maura N. Dickler, MD / August 10, 2017

A New Triumvirate in Estrogen Receptor–Positive Metastatic Breast Cancer

THE BODY OF EVIDENCE supporting the use of cell-cycle inhibitors in combination with endocrine therapy for estrogen receptor–positive metastatic breast cancer now has another agent in the spotlight. The phase III MONARCH 2 trial—reported at the 2017 ASCO Annual Meeting and by Sledge et al in the...

May

Today In Oncology

Search Results

Your search for Neil Vasan, MD, PhD, and Maura N. Dickler, MD,Neil Vasan, MD, PhD, and Maura N. Dickler, MD matches 2 pages

Abemaciclib Plus Endocrine Therapy Extends Progression-Free Survival in First-Line Therapy for Advanced Breast Cancer

A New Triumvirate in Estrogen Receptor–Positive Metastatic Breast Cancer

Glecirasib Shows Efficacy and Safety in KRAS G12C–Mutated NSCLC

Metastatic Castration-Resistant Prostate Cancer Addition of LuPSMA to Enzalutamide

Breast Implant–Related Cancers: Should Our Patients Be Concerned?

Pediatric AML Comparison of Induction Regimens

Older Patients With Newly Diagnosed Hodgkin Lymphoma Preexisting Heart Failure and Survival Outcomes